Clinical Decision Trees to Guide Physical Therapy Management of Persons with Huntington's Disease

被引:2
|
作者
Fritz, Nora E. [1 ,2 ]
Kegelmeyer, Deb A. [3 ]
Rao, Ashwini K. [4 ]
Quinn, Lori [5 ]
Kloos, Anne D. [3 ]
机构
[1] Wayne State Univ, Dept Hlth Care Sci, 259 Mack Ave 2324, Detroit, MI 48201 USA
[2] Wayne State Univ, Dept Neurol, 259 Mack Ave 2324, Detroit, MI 48201 USA
[3] Ohio State Univ, Sch Hlth & Rehabil Sci, Phys Therapy Div, Columbus, OH 43210 USA
[4] Columbia Univ, GH Sergievsky Ctr, Dept Rehabil & Regenerat Med, Program Phys Therapy, New York, NY USA
[5] Columbia Univ, Teachers Coll, Dept Biobehav Sci, New York, NY 10027 USA
关键词
Assessment; plan of care; exercise; rehabilitation; algorithms; guidelines; QUALITY-OF-LIFE; TINETTI MOBILITY TEST; EXERCISE PROGRAM; RATING-SCALES; WHODAS; 2.0; INDIVIDUALS; BALANCE; PEOPLE; FEASIBILITY; RELIABILITY;
D O I
10.3233/JHD-220549
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: In 2020, our group published physical therapy clinical practice guidelines (CPG) for people with Huntington's disease (HD). The guideline recommendations were categorized according to six primary movement impairment classifications. Objective: To facilitate implementation of this CPG, we have developed guideline-based algorithms for physical therapy assessments and interventions and recommendations for therapists to overcome barriers to CPG implementation for people with HD. Methods: We conducted a literature review of papers that evaluated physical therapy interventions in individuals with HD (n = 26) to identify assessments for each of the primary movement impairment classifications, and then searched for papers (n = 28) that reported their clinometric/psychometric properties in HD. Assessments were evaluated using modifiedMovement Disorder Society Committee on Rating Scales criteria and other relevant criteria. Results: We identified a "core set" of physical therapy assessments for persons with HD, including the Six MinuteWalk Test, Timed Up and Go Test, Berg Balance Scale, and the Medical Outcomes Study Short Form 36 (SF-36). We then developed guideline-based decision trees to assist in decision making and implementation of the CPG into practice for persons with HD across the continuum of care. Finally, we developed strategies for overcoming barriers to implementation, such as seeking specialized training in HD, engaging caretakers or family members to help the person with HD to exercise, and establishing clinical pathways that support early physical therapy referrals. Conclusion: Knowledge translation documents such as this are essential to promoting implementation of the physical therapy CPGs into clinical practice.
引用
收藏
页码:435 / 453
页数:19
相关论文
共 50 条
  • [41] Clinical Features of Huntington's Disease
    Ghosh, Rhia
    Tabrizi, Sarah J.
    POLYGLUTAMINE DISORDERS, 2018, 1049 : 1 - 28
  • [42] Wilson's disease: clinical management and therapy
    Brewer, GJ
    Askari, FK
    JOURNAL OF HEPATOLOGY, 2005, 42 : S13 - S21
  • [43] Communication and Huntington's disease: qualitative interviews and focus groups with persons with Huntington's disease, family members, and carers
    Hartelius, Lena
    Jonsson, Maria
    Rickeberg, Anneli
    Laakso, Katja
    INTERNATIONAL JOURNAL OF LANGUAGE & COMMUNICATION DISORDERS, 2010, 45 (03) : 381 - 393
  • [44] High suicidal ideation in persons testing for Huntington's disease
    Wahlin, TBR
    Bäckman, L
    Lundin, A
    Haegermark, A
    Winblad, B
    Anvret, M
    ACTA NEUROLOGICA SCANDINAVICA, 2000, 102 (03): : 150 - 161
  • [45] Moral judgment and decision making in Huntington's disease
    Eddy, C. M.
    Rickards, H. E.
    BASAL GANGLIA, 2012, 2 (03) : 139 - 142
  • [46] Gene therapy for Parkinson's and Huntington's disease
    Kordower, JH
    McBride, J
    MOVEMENT DISORDERS, 2004, 19 : S8 - S8
  • [47] PERK ACTIVATION THERAPY IN HUNTINGTON'S DISEASE
    Shacham, Talya
    Lederkrember, Gerardo
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 : A95 - A95
  • [48] Cell and gene therapy for Huntington's disease
    Song, Jihwan
    TISSUE ENGINEERING PART A, 2022, 28 : 346 - 346
  • [49] Synthetic siRNAs for Huntington's Disease Therapy
    Staber, Patrick D.
    Vargeese, Chandra
    Martins, Ines H.
    Polisky, Barry
    Mas-Monteys, Alex
    Harper, Scott Q.
    Davidson, Beverly L.
    MOLECULAR THERAPY, 2006, 13 : S36 - S37
  • [50] Therapy in Huntington's Disease: Where Are We?
    Nance, Martha A.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2012, 12 (04) : 359 - 366